Groupama Asset Managment Raises Position in Pfizer Inc. (NYSE:PFE)

Groupama Asset Managment increased its position in Pfizer Inc. (NYSE:PFE) by 2.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 289,101 shares of the biopharmaceutical company’s stock after buying an additional 5,604 shares during the quarter. Groupama Asset Managment’s holdings in Pfizer were worth $8,367,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer in the 2nd quarter worth $29,000. Gladius Capital Management LP raised its position in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the period. Quarry LP purchased a new position in shares of Pfizer in the 2nd quarter worth $31,000. Financial Connections Group Inc. purchased a new position in shares of Pfizer in the 2nd quarter worth $34,000. Finally, Teachers Insurance & Annuity Association of America purchased a new position in shares of Pfizer in the 3rd quarter worth $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.1 %

Shares of Pfizer stock opened at $25.73 on Monday. The company has a market capitalization of $145.81 billion, a PE ratio of 34.77, a P/E/G ratio of 0.70 and a beta of 0.65. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The business has a 50-day moving average of $27.47 and a 200-day moving average of $28.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.17) earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were paid a $0.42 dividend. The ex-dividend date of this dividend was Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.53%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insider Buying and Selling

In other news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Wolfe Research began coverage on Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Finally, Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $32.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.